BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1187 related articles for article (PubMed ID: 19812061)

  • 1. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
    Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
    Kim YH; Yamaguchi K; Bang YJ; Takiuchi H; Kang WK; Sato A; Kang YK; Sakamoto J; Abe C; Sakata Y
    Jpn J Clin Oncol; 2007 Jul; 37(7):501-8. PubMed ID: 17673470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.
    Park SR; Oh DY; Kim DW; Kim TY; Heo DS; Bang YJ; Kim NK; Kang WK; Kim HT; Im SA; Suh JH; Kim HK; Kim HK
    Oncol Rep; 2004 Nov; 12(5):1059-64. PubMed ID: 15492793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
    Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer.
    Nagata N; Kimura M; Hirabayashi N; Tuburaya A; Murata T; Kondo K; Fukuda Y; Kobayashi M; Miyashita Y; Nakao A; Sakamoto J
    Hepatogastroenterology; 2008; 55(86-87):1846-50. PubMed ID: 19102406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
    J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
    Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
    Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
    Hatori S; Kunisaki C; Ono H; Sato T; Otsuka Y; Yamada R; Ohshima T; Rino Y; Imada T
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1257-60. PubMed ID: 16969021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.